Evaxion announces business update and full year 2024 financial results
Provided By GlobeNewswire
Last update: Apr 1, 2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.
Read more at globenewswire.comNASDAQ:EVAX (9/23/2025, 11:55:22 AM)
3.1523
+0.1 (+3.35%)
Find more stocks in the Stock Screener
